TUMOR-ANTIGENS RECOGNIZED BY CYTOLYTIC T-LYMPHOCYTES - PRESENT PERSPECTIVES FOR SPECIFIC IMMUNOTHERAPY
TUMOR-ANTIGENS RECOGNIZED BY CYTOLYTIC T-LYMPHOCYTES - PRESENT PERSPECTIVES FOR SPECIFIC IMMUNOTHERAPY
复制标题
DOI：
10.1002/ijc.2910540202
复制
发表时间：
1993-05-08
影响因子：
6.4
通讯作者：
BOON, T
中科院分区：
文献类型：
--
作者：
BOON, T
第一个基因编码的小鼠和人类肿瘤排斥抗原识别的T淋巴细胞现已被分离出来，它是一个可能的前景，几个额外的人类基因将在不久的将来被确定。我将在这里简要总结我们的发现，并讨论它们如何为特定的癌症免疫治疗带来新的可能性。我们的方法一直严格限制于那些抗原的细胞溶解性T淋巴细胞（CTL）识别。这并不意味着CTL的破坏是肿瘤排斥的唯一甚至最有效的机制。事实上，我们已经遇到几例在几乎不存在可检测的CTL的情况下非常强烈的肿瘤排斥的病例（布恩和Kellermann，1977;布恩和货车Pel，1978）。但是CTL克隆已被证明是非常有用和可靠的试剂，其可以支持用于分析肿瘤排斥抗原的遗传方法（韦斯et al.，1980年）。此外，CTL免疫受体识别位于I类主要组织相容性复合体（MHC）分子凹槽中的小肽的证明使得对遗传结果的完整解释成为可能
The first genes coding for mouse and human tumor-rejection antigens recognized by T lymphocytes have now been isolated, and it is a likely prospect that several additional human genes will be identified in the near future. I shall attempt here to briefly summarize our findings and discuss how they lead to new possibilities for specific cancer immunotherapy. Our approach has been strictly limited to those antigens that are recognized by cytolytic T lymphocytes (CTL). This does not by any means reflect the belief that destruction by CTL is the only or even the most effective mechanism of tumor rejection. In fact, we have encountered several cases of very strong tumor rejection in the near-absence of detectable CTL (Boon and Kellermann, 1977; Boon and Van Pel, 1978). But CTL clones have proved extremely useful and reliable reagents that could support a genetic approach towards the analysis of tumor-rejection antigens (Weiss et al., 1980). Moreover, the demonstration that the immune receptor of CTL recognizes small peptides located in a groove of class-I major histocompatibility complex (MHC) molecules has made it possible to obtain a complete interpretation of thc genetic results